- Home
- AGIO vs KMT Comparison
AGIO vs KMT Comparison
Compare AGIO & KMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- KMT
- Stock Information
- Founded
- AGIO 2007
- KMT 1938
- Country
- AGIO United States
- KMT United States
- Employees
- AGIO N/A
- KMT N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- KMT Industrial Machinery/Components
- Sector
- AGIO Health Care
- KMT Industrials
- Exchange
- AGIO Nasdaq
- KMT Nasdaq
- Market Cap
- AGIO 2.0B
- KMT 1.7B
- IPO Year
- AGIO 2013
- KMT N/A
- Fundamental
- Price
- AGIO $30.28
- KMT $21.62
- Analyst Decision
- AGIO Buy
- KMT Hold
- Analyst Count
- AGIO 8
- KMT 5
- Target Price
- AGIO $56.57
- KMT $26.40
- AVG Volume (30 Days)
- AGIO 637.9K
- KMT 1.0M
- Earning Date
- AGIO 05-01-2025
- KMT 05-07-2025
- Dividend Yield
- AGIO N/A
- KMT 3.70%
- EPS Growth
- AGIO N/A
- KMT N/A
- EPS
- AGIO 11.64
- KMT 1.22
- Revenue
- AGIO $36,498,000.00
- KMT $2,023,102,000.00
- Revenue This Year
- AGIO $50.61
- KMT N/A
- Revenue Next Year
- AGIO $223.79
- KMT $1.91
- P/E Ratio
- AGIO $2.60
- KMT $17.70
- Revenue Growth
- AGIO 36.07
- KMT N/A
- 52 Week Low
- AGIO $27.14
- KMT $20.50
- 52 Week High
- AGIO $62.58
- KMT $32.18
- Technical
- Relative Strength Index (RSI)
- AGIO 39.54
- KMT 44.64
- Support Level
- AGIO $30.00
- KMT $21.30
- Resistance Level
- AGIO $32.90
- KMT $22.72
- Average True Range (ATR)
- AGIO 1.22
- KMT 0.56
- MACD
- AGIO -0.08
- KMT 0.10
- Stochastic Oscillator
- AGIO 9.12
- KMT 39.23
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.